25+ years
of experience in organ transplantation
of experience in organ transplantation
100+ countries
with PROGRAF® available
with PROGRAF® available
60+ countries
with ADVAGRAF® available
with ADVAGRAF® available
Astellas is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting a Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. We are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions combining our expertise and knowledge with cutting-edge technology in different fields of external partners.
With over 25 years of dedication in support of the advancement of care for transplant patients, we continue to build upon our legacy of providing innovative life-saving and life-changing immunosuppressant therapies for patients undergoing transplantation for patients around the world.
Through all these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.
Tacrolimus Prevention of Rejection
88.1% graft survival rates at 4 years with ADVAGRAF®
93.8% patient survival rates at 4 years with ADVAGRAF®
8% difference in graft survival with ADVAGRAF® vs tacrolimus BID (p=0.002)
7% difference in patient survival with ADVAGRAF® vs tacrolimus BID (p=0.003)
